BRCA1 and glioblastoma: Additionally, RRM2 expression positively correlated with that of BRCA1 and both the percentage of BRCA1+ and RRM2+ cells correlated negatively with glioma patient survival (Fig. 6c,e,f,h; Supplementary Fig. 5c,e), thus making RRM2 an attractive candidate for therapeutic targeting in GBM.